Phase IIb/III trial of multidoses of fasinumab (NGF mAb) in 421 pts w/ mod‐severe hip or knee #OA (WOMAC pain ~6+) showed signif reductions in pain (LMS -1.1 to -1.4) vs PBO (-.79) & >30% improved pain by @wk16 (63–74 vs 47%); arthropathy 7% FAS vs 1%PBO https://t.co/UtkqDE5lGf